Seronegative fibrosing cholestatic hepatitis С after liver retransplantation for unresectable neuroendocrine tumor liver metastases
Open Access
- 11 December 2020
- journal article
- Published by IPO Association of Transplantologists in Transplantologiya
- Vol. 12 (4), 319-331
- https://doi.org/10.23873/2074-0506-2020-12-4-319-331
Abstract
We present an uncommon case of liver graft dysfunction caused by seronegative hepatitis C-related fibrosing cholestatic hepatitis after cadaver liver transplantation for unresectable liver metastases of neuroendocrine small intestine cancer followed by living relation donor liver fragment retransplantation for primary graft nonfunction. Early postoperative period was complicated by hepatic artery thrombosis, cerebral hemorrhage, acute cellular rejection, bilateral polysegmental pneumonia, bleeding into neck soft tissues, severe surgical site infection, and sepsis. Anticoagulant therapy, as well as the absence of Hepatitis C Virus antibodies made difficult early diagnostics of fibrosing cholestatic hepatitis. A present-day antiviral therapy produced a complete clinical and virological response. At control examination performed at 240 days after surgery, there were neither signs of cancer progression no graft dysfunction. Liver transplantation in that case was an example of radical and effective treatment method for unresectable liver metastases of neuroendocrine small intestine cancer. Timely diagnosis and proper treatment of fibrosing cholestatic hepatitis made it possible to save the liver graft and patient's life.This publication has 23 references indexed in Scilit:
- Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver TransplantationClinical Gastroenterology and Hepatology, 2015
- P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantationJournal of Hepatology, 2015
- Liver transplantation for neuroendocrine tumour liver metastasesHPB, 2015
- Recommendations for management of patients with neuroendocrine liver metastasesThe Lancet Oncology, 2014
- Seronegative Hepatitis C Virus InfectionArchivum Immunologiae et Therapiae Experimentalis, 2013
- Post-liver transplant cholestatic hepatitis C: A systematic review of clinical and pathological findings and application of consensus criteriaLiver Transplantation, 2010
- Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirinJournal of Hepatology, 2008
- High levels of subgenomic HCV plasma RNA in immunosilent infectionsVirology, 2007
- Interferon-Based Combination Anti-Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative AnalysisAmerican Journal of Transplantation, 2006
- Clinicopathological features of rapidly progressive hepatitis C virus infection in HCV antibody negative renal transplant recipients.Nephrology Dialysis Transplantation, 1998